OSUR250117C2500
- 1.55
- 0.000.00%
OraSure Technologies Newsroom
OraSure to Present at the J.P Morgan Healthcare Conference
Express News | OraSure Technologies Shares up 4% Premarket After Oraquick® Hiv Self-Test Approved for Use in Adolescents
OraQuick HIV Self-Test Gains Approval For Adolescents, Expanding Access To HIV Testing For Ages 14 And Up
Fluctuations are expected to continue in the early days of Trump's presidency, with Citigroup favoring Medical, Financial, and other defensive Industries.
In the market volatility and uncertainty following Trump's inauguration, defensive industries such as Medical Care and finance are favored in the model portfolio created by Citigroup strategists.
Evercore Maintains OraSure Technologies(OSUR.US) With Hold Rating, Cuts Target Price to $4
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
Express News | OraSure Technologies Inc - Sherlock's Ct/Ng Self-Test Expected to Be Submitted to FDA by End of 2025
Press Release: OraSure Technologies Acquires Sherlock Biosciences
Express News | OraSure Technologies Acquires Sherlock Biosciences
OraSure Secures $7.5M Contract With $11M Potential for Marburg Virus Rapid Test Development
Express News | OraSure Technologies : Initial Contract Award, Valued at About $7.5 Mln Over Multiple Years in Base Period With Potential Value up to $11 Mln
Express News | OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
Is OraSure Technologies (OSUR) Stock Undervalued Right Now?
OraSure to Participate in Upcoming Investor Conference
There May Be Some Bright Spots In OraSure Technologies' (NASDAQ:OSUR) Earnings
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript Summary
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies | 10-Q: Q3 2024 Earnings Report
OraSure Technologies Non-GAAP EPS of -$0.01 Beats by $0.01, Revenue of $39.92M Beats by $0.9M
OraSure Technologies Shifts Focus Amid Revenue Drop